AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6336714 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein diet
Number of subjects: 8
Study 6336714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable protein diet
Number of subjects: 8
Study 6336714 — intervention group
Group type: COMPARATOR
Intervention: Mixed protein diet
Number of subjects: 8
Study 31850484 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mouthwash formulation containing natural antibiofilm agents
Number of subjects: 30
Study 31850484 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 30
Study 31850484 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mouthwash formulation
Number of subjects: 30
Study 31317942 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic partial papillosphincterotomy combined with balloon dilatation (main group A)
Number of subjects: 90
Study 31317942 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic papillosphincterotomy (clinical comparison 1)
Number of subjects: 90
Study 31317942 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic papillosphincterotomy with mechanical lithotripsy (clinical comparison 2)
Number of subjects: 90
Study 28656510 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil hydration (10 μg/day for 3 days plus 20 ml normal saline)
Number of subjects: 451
Study 28656510 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 ml normal saline for 3 days)
Number of subjects: 451
Study 24691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-oriented smoking cessation program
Number of subjects: 590
Study 24691565 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 590
Study 23321226 — intervention group
Group type: EXPERIMENTAL
Intervention: Foraminal enlargement instrumentation
Number of subjects: 40
Study 23321226 — intervention group
Group type: COMPARATOR
Intervention: Standard nonenlargement instrumentation (Control)
Number of subjects: 40
Study 21730076 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 21730076 — intervention group
Group type: COMPARATOR
Intervention: Calcium-channel blockers
Number of subjects: 0
Study 21730076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 19501611 — intervention group
Group type: EXPERIMENTAL
Intervention: Equiluminant weaves
Number of subjects: 0
Study 19501611 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance-mismatched weaves
Number of subjects: 0
Study 16876058 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 20
Study 16876058 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine with 1:100,000 epinephrine
Number of subjects: 20
Study 15316192 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening dentifrice
Number of subjects: 14
Study 15316192 — intervention group
Group type: COMPARATOR
Intervention: Regular dentifrice
Number of subjects: 14
Study 10776363 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Management Program (DMP)
Number of subjects: 407
Study 9348365 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis IgG titers positive
Number of subjects: 51
Study 9348365 — intervention group
Group type: EXPERIMENTAL
Intervention: Age analysis of positive Chlamydia trachomatis IgG titers
Number of subjects: 51
Study 9348365 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae titers positive
Number of subjects: 51
Study 9348365 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis titers positive
Number of subjects: 51
Study 8375999 — intervention group
Group type: EXPERIMENTAL
Intervention: Interslice compression algorithm at compression ratios of 5:1, 10:1, and 15:1
Number of subjects: 3
Study 8375999 — intervention group
Group type: COMPARATOR
Intervention: Intraslice compression algorithm at compression ratios of 5:1, 10:1, and 15:1
Number of subjects: 3
Study 8375999 — intervention group
Group type: EXPERIMENTAL
Intervention: Interslice compression algorithm at 10:1
Number of subjects: 3
Study 8375999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement among radiologists
Number of subjects: 3
Study 3532009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg three times a day for 4 weeks)
Number of subjects: 22
Study 3532009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to nifedipine, three times a day for 4 weeks)
Number of subjects: 22
Study 29715355 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (n=460)
Number of subjects: 914
Study 29715355 — intervention group
Group type: COMPARATOR
Intervention: Insulin (n=454)
Number of subjects: 914
Study 28049818 — intervention group
Group type: COMPARATOR
Intervention: Short-chain galactooligosaccharide (GOS) treatment, designated 'RP-G28', administered over 36 days.
Number of subjects: 30
Study 26022709 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAM (flavopiridol 50 mg/m(2) days 1‐3, cytarabine 667 mg/m(2)/day continuous infusion days 6‐8, and mitoxantrone 40 mg/m(2) day 9)
Number of subjects: 165
Study 26022709 — intervention group
Group type: COMPARATOR
Intervention: 7+3 (cytarabine 100 mg/m(2)/day continuous infusion days 1‐7 and daunorubicin 90 mg/m(2) days 1‐3)
Number of subjects: 165
Study 26022709 — intervention group
Group type: COMPARATOR
Intervention: 7+3+/-5+2 (cytarabine 100 mg/m(2)/day continuous infusion days 1‐5 and daunorubicin 45 mg/m(2) days 1‐2)
Number of subjects: 165
Study 23471041 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (ICED) - deceived of the actual cycling intensity
Number of subjects: 16
Study 23471041 — intervention group
Group type: COMPARATOR
Intervention: Control group (ICEC) - informed of the actual protocol
Number of subjects: 16
Study 21497022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg followed by two boluses of 0.5 mg/kg at 5-min intervals and continuous infusion)
Number of subjects: 45
Study 21497022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride administered at equivalent volume, dose and rate to lidocaine)
Number of subjects: 45
Study 18227847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling (ten 1-hour consultations)
Number of subjects: 50
Study 16421781 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer upper arm vaccination
Number of subjects: 20
Study 16421781 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner upper arm vaccination
Number of subjects: 20
Study 16421781 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 12925034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin (bolus 0.1 mg kg‐1, continuous infusion of 0.1 mg kg‐1 h‐1)
Number of subjects: 24
Study 12925034 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 12162483 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC-containing solution
Number of subjects: 35
Study 12162483 — intervention group
Group type: COMPARATOR
Intervention: Multipurpose solutions without HPMC
Number of subjects: 35
Study 9672932 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding oral fluids for 4-6 hours postoperatively
Number of subjects: 317
Study 9672932 — intervention group
Group type: COMPARATOR
Intervention: Drinking oral fluids postoperatively
Number of subjects: 317
Study 9672932 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding oral fluids in patients receiving opioids
Number of subjects: 317
Study 7916445 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and chlordesmethyldiazepam (0.03 mg/kg)
Number of subjects: 40
Study 7916445 — intervention group
Group type: COMPARATOR
Intervention: Atropine and diazepam (0.015 mg/kg)
Number of subjects: 40
Study 2690395 — intervention group
Group type: EXPERIMENTAL
Intervention: 252Cf neutron component applied by means of intracavitary therapy at the beginning of the therapeutic cure
Number of subjects: 56
Study 2690395 — intervention group
Group type: COMPARATOR
Intervention: Conventional 226Ra therapy (control group)
Number of subjects: 56
Study 2690395 — intervention group
Group type: EXPERIMENTAL
Intervention: 252Cf neutron component
Number of subjects: 56
Study 30981620 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH
Number of subjects: 684
Study 30981620 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 684
Study 28939164 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 90
Study 28939164 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 90
Study 25599450 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up modulation (stimulus intensity)
Number of subjects: 0
Study 25599450 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down modulation (placebo analgesia)
Number of subjects: 0
Study 22633681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking (as a prognostic factor)
Number of subjects: 660
Study 22633681 — intervention group
Group type: COMPARATOR
Intervention: Poor recovery trend group (patterns 4-14)
Number of subjects: 660
Study 21192304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 or 400 mcg)
Number of subjects: 26
Study 21192304 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone (40 mg)
Number of subjects: 26
Study 19523011 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 microg week(‐1) PEG‐IFN alpha‐2a (40KD) + ribavirin (1000/1200 mg day(‐1)) for 48 weeks
Number of subjects: 40
Study 19523011 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 microg week(‐1) PEG‐IFN alpha‐2a (40KD) + ribavirin (1000/1200 mg day(‐1)) for 48 weeks
Number of subjects: 40
Study 17577435 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific treatment group (intravascular embolism followed by immediate CSF drainage)
Number of subjects: 84
Study 17577435 — intervention group
Group type: COMPARATOR
Intervention: Conventional expectant treatment group
Number of subjects: 84
Study 14710138 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal bulb suctioning at birth
Number of subjects: 20
Study 14710138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bulb suctioning)
Number of subjects: 20
Study 14710138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 11432512 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision
Number of subjects: 150
Study 11432512 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment with 0.2% glyceryl trinitrate ointment
Number of subjects: 150
Study 10052665 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX (high-low exercise order) - starts with intense sprints followed by less intense sprints
Number of subjects: 11
Study 10052665 — intervention group
Group type: EXPERIMENTAL
Intervention: LHX (low-high exercise order) - starts with less intense sprints followed by intense sprints
Number of subjects: 11
Study 10052665 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX
Number of subjects: 11
Study 10052665 — intervention group
Group type: EXPERIMENTAL
Intervention: LHX
Number of subjects: 11
Study 8205085 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperimmune immunoglobulins
Number of subjects: 0
Study 8205085 — intervention group
Group type: COMPARATOR
Intervention: no immunoglobulins (control)
Number of subjects: 0
Study 30240771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clips
Number of subjects: 70
Study 30240771 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar cauterization
Number of subjects: 70
Study 26346997 — intervention group
Group type: EXPERIMENTAL
Intervention: S- (stopcock disconnected)
Number of subjects: 60
Study 26346997 — intervention group
Group type: COMPARATOR
Intervention: S+ (stopcock attached)
Number of subjects: 60
Study 24632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic AF
Number of subjects: 157
Study 24632222 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic AF
Number of subjects: 157
Study 23068960 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 160
Study 23068960 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 160
Study 20037779 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (FEC-P)
Number of subjects: 0
Study 20037779 — intervention group
Group type: COMPARATOR
Intervention: FEC (control)
Number of subjects: 0
Study 19065852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligned zigzag line patterns
Number of subjects: 0
Study 19065852 — intervention group
Group type: EXPERIMENTAL
Intervention: Steepness and density of angles in aligned-angle patterns
Number of subjects: 0
Study 15726659 — intervention group
Group type: EXPERIMENTAL
Intervention: EVL plus nadolol
Number of subjects: 80
Study 15726659 — intervention group
Group type: COMPARATOR
Intervention: EVL alone
Number of subjects: 80
Study 12927007 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15‐45 mg/day)
Number of subjects: 133
Study 12927007 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20‐40 mg/day)
Number of subjects: 133
Study 12927007 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 133
Study 12927007 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 133
Study 10365573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of exercise
Number of subjects: 27
Study 10365573 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-strenuous exercise
Number of subjects: 27
Study 8777930 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breast milk for at least 4 weeks (n = 206)
Number of subjects: 702
Study 8777930 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk plus extensively hydrolysed formula (n = 50)
Number of subjects: 702
Study 8777930 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed cow's milk formula for 2 months, followed by conventional cow's milk (n = 82)
Number of subjects: 702
Study 8777930 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk plus initial conventional cow's milk formula (n = 73)
Number of subjects: 702
Study 8777930 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cow's milk with or without breast milk throughout (n = 187)
Number of subjects: 702
Study 8777930 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk plus initial partially hydrolysed formula (n = 104)
Number of subjects: 702
Study 2053556 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 69
Study 2053556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 6683566 — intervention group
Group type: COMPARATOR
Intervention: Argon laser photocoagulation
Number of subjects: 11
Study 6683566 — intervention group
Group type: COMPARATOR
Intervention: Xenon arc photocoagulation
Number of subjects: 11
Study 29734896 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg triamcinolone acetonide
Number of subjects: 93
Study 29734896 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg triamcinolone acetonide
Number of subjects: 93
Study 29734896 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone acetonide
Number of subjects: 93
Study 27448667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendiocarb
Number of subjects: 2704
Study 27448667 — intervention group
Group type: COMPARATOR
Intervention: Deltamethrin
Number of subjects: 2704
Study 24597289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of GnRH agonist with recombinant hCG (rhCG)
Number of subjects: 120
Study 24597289 — intervention group
Group type: COMPARATOR
Intervention: rhCG alone
Number of subjects: 120
Study 22730390 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 4 × 5‐min 220‐mmHg bilateral occlusion
Number of subjects: 13
Study 22730390 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention - 4 × 5‐min 20‐mmHg bilateral occlusion
Number of subjects: 13
Study 20431040 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and prednisolone
Number of subjects: 489
Study 20431040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine monotherapy
Number of subjects: 489
Study 20431040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine monotherapy followed by azathioprine and prednisolone after 3 months
Number of subjects: 489
Study 20431040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 489
Study 18378552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (MECA, 20 mg, oral)
Number of subjects: 6
Study 18378552 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (SCOP, 2.5 microg/kg, i.v.)
Number of subjects: 6
Study 18378552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 16006574 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 818
Study 16006574 — intervention group
Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 818
Study 12449254 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape instruction for home exercise program
Number of subjects: 0
Study 12449254 — intervention group
Group type: COMPARATOR
Intervention: Personal instruction by a physical therapist
Number of subjects: 0
Study 10359889 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol xinafoate 42 microgram twice daily
Number of subjects: 0
Study 10359889 — intervention group
Group type: COMPARATOR
Intervention: Oral zafirlukast 20 mg twice daily
Number of subjects: 0
Study 8984127 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial SBP change in Parkinson's disease patients
Number of subjects: 20
Study 8984127 — intervention group
Group type: COMPARATOR
Intervention: Postprandial SBP change in control patients
Number of subjects: 20
Study 8984127 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic SBP responses in Parkinson's disease patients
Number of subjects: 20
Study 8984127 — intervention group
Group type: COMPARATOR
Intervention: Orthostatic SBP responses in control patients
Number of subjects: 20
Study 8984127 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic heart rate responses in Parkinson's disease patients
Number of subjects: 20
Study 8984127 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of meal on orthostatic blood pressure
Number of subjects: 20
Study 1709240 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg b.i.d.)
Number of subjects: 66
Study 1709240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg o.d.)
Number of subjects: 66
Study 1709240 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and chlorthalidone (20 mg b.i.d. and 25 mg o.d.)
Number of subjects: 66
Study 1709240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 6451257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms by nebuliser)
Number of subjects: 28
Study 6451257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide given two hours before or after nebulised salbutamol
Number of subjects: 28
Study 6451257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide in addition to salbutamol
Number of subjects: 28
Study 31178377 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTAVAC® (3 doses)
Number of subjects: 464
Study 31178377 — intervention group
Group type: COMPARATOR
Intervention: Rotarix® (2 doses)
Number of subjects: 464
Study 28631502 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent infarct-related artery (TIMI flow 2/3)
Number of subjects: 1863
Study 27177231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 27177231 — intervention group
Group type: COMPARATOR
Intervention: CHO-only
Number of subjects: 8
Study 27177231 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-casein
Number of subjects: 8
Study 27177231 — intervention group
Group type: COMPARATOR
Intervention: CHO-whey
Number of subjects: 8
Study 25052936 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous distance-education technology (online delivery)
Number of subjects: 1711
Study 25052936 — intervention group
Group type: COMPARATOR
Intervention: In-person delivery (control)
Number of subjects: 1711
Study 23106838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealant with oral hygiene instructions
Number of subjects: 60
Study 23106838 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions only (Control)
Number of subjects: 60
Study 23106838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealant
Number of subjects: 60
Study 19918250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 776
Study 19918250 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional low‐fat diet)
Number of subjects: 776
Study 17764475 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise starting immediately after dosing (EX0)
Number of subjects: 12
Study 17764475 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise starting 30 min after dosing (EX30)
Number of subjects: 12
Study 17764475 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NOEX)
Number of subjects: 12
Study 15926116 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 16
Study 15926116 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RHI)
Number of subjects: 16
Study 12691686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain hot line
Number of subjects: 64
Study 12691686 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly provider-initiated follow-up calls for 1 month post-education
Number of subjects: 64
Study 12691686 — intervention group
Group type: COMPARATOR
Intervention: Baseline pain education program
Number of subjects: 64
Study 12691686 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 11115255 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress
Number of subjects: 308
Study 11115255 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infection
Number of subjects: 308
Study 11115255 — intervention group
Group type: EXPERIMENTAL
Intervention: Other exposure variables (sunlight exposure, menstrual period, contact lens wear, eye injury)
Number of subjects: 308
Study 11115255 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective reporting of high stress
Number of subjects: 308